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1. Introduction
  HS-4 is a compound isolated from Mangrove Kandelia candel in 
Dongzhaigang, Hainan province in China. Its molecular weight is 
529, and the molecular formula is C25H30O14. The structural formula 
is shown in figure 1. It was demonstrated by the results of in vitro 
antitumor experiment to have relatively high antitumor activity 
against liver cancer cells. Primary hepatic carcinoma (PHC) is one 
of the most deadly cancers[1], and there are 626 000 new cases 
presented every year in China, more than half a million people are 
died from liver cancer[2]. China has become the country with highest 
incidence of liver cancer in the world[3], which accounts for about 
55% in the world[3]. The causes of death in patients with liver cancer 
are primarily related to the high metastasis and high recurrence[1]. 
At present, chemotherapy is still an important treatment method 
for liver cancer[3], but issues such as the drug resistance, liver 
cirrhosis and hepatic hypofunction are often presented in treatment. 
Therefore, it is becoming increasingly urgent for seeking new 
antitumor drugs, new prognostic markers and therapeutic targets. 
2. Materials and methods
2.1. Material 
  HS-4 was prepared by our laboratory, the chemical name: 10-
(4- hydroxy-3’,’5’-dimethoxy benzoic acyl)-Geniposidic acid, the 
molecular weight is 529, the molecular formula is C25H30O14. The 
liver cancer cells (Bel-7402 and SMMC-7721), gastric cancer cells 
(MGC-803H and SGC-7901), breast cancer cells(MCF-7), renal 
cancer cells (TE-1) and colon cancer cells (HT-29) were purchased 
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from Shanghai Cell Bank of Chinese Academy of Sciences, while 
the bio-luminescence marking was performed for Bel-7402 by 
Shanghai Lecheng Biological Technology Co., Ltd ,China. RPMI 
1640 culture medium was purchased from G ibco (NewYork, NY, 
USA). Trypsin-ethylenediamine tetraacetic acid  (EDTA), MTT, 
and dimethyl sulfoxide  (DMSO) were purchased from  Sigma (St. 
Louis, MO , USA). Fetal bovine serum (FBS) was from Zhejiang 
Tian hang Biological Technology Co., Ltd., China (Hangzhou, 
Zhejiang Province, China). BALB/c nude mice were purchased from 
the Medical Experimental Animal Center of Guangdong province, 
China.
2.2. In vitro antitumor experiment
  MTT method was used to screen in vitro antitumor activity of the 
compound HS-4 against tumor cells. The tumor cell was cultured 
in cell culture bottles, and digested with 0.25% Trypsin-EDTA. The 
cells were collected by centrifugation to prepare cell suspension, 
and they were added to 96-well plate by 4 000 cells/200 AL/well. 
Then the cells were put into CO2 incubator for culture (concentration 
of CO2 was 5%, the temperature was 37 曟). After cultured 
for 24 hours, 2 毺L of compound HS-4 DMSO solution with 
different concentrations was added into the cells. Then cells were 
continuously cultured for another 24 hours, before 20 毺L (5 mg/
mL) MTT solution was added. After the MTT solution addition, the 
cells were cultured for another 4 hours, the liquid in 96 well-plate 
was carefully removed, 150 毺L DMSO was added to each well. OD 
value was tested with ELIASA at detection wave length of 492 nm. 
At the end, the in-vitro tumor inhibitory rate of compound HS-4 was 
calculated with the formula as below:
IR %=(1-ODHS-4/OD contrast) ×100% and IC50 values.
2.3. Establishment of subcutaneous xenotransplantation 
model of tumor
  Healthy BALB/c nude mice were selected, and 0.2 mL suspension 
of tumor cells with cell concentration of about 1暳10
7 cells/mL was 
subcutaneously injected at their right axillary fossa. Put the mice 
back to the cage to breed after injection was completed, and observe 
growth of tumor cells. 
2.4. Therapeutic effect of compound HS-4 in multiple 
subcutaneously xenotransplanted tumor
  We had established subcutaneously xenotransplanted tumor model 
of liver cancer cell Bel-7402, gastric cancer cell SGC-7901, renal 
cancer cell ACHN, lung cancer cell A549, breast cancer cell MCF-7 
and colon cancer cell HT-29 in nude mice to screen in vivo antitumor 
activity of compound HS-4. The mice were divided into HS-4 group 
and solvent control group in the experiment, wherein, HS-4 was 
classified into 3 dose groups based on the dosage provided as 4, 2 
and 10 mg/kg, respectively. There were 6 animals in each group, and 
the route of administration was intragastric medication. Time of drug 
administration: 14 d. 
2.5. Establishment of orthotopic xenotransplanted tumor 
model of liver cancer
  Successfully subcutaneously transplanted solid tumor of liver 
cancer under normal growth was taken to cut into small pieces with 
scalpel (2 mm×2 mm×1 mm), and rinse 3 times with proper amount 
of RPMI-1640 medium containing no fetal bovine serum, then, 
the tumor mass was placed into sterile, dry culture dish and proper 
amount of RPMI-1640 culture solution containing no fetal bovine 
serum was added for spare use. Gas anesthesia was performed in 
healthy nude mice using isoflurane, supine position was taken, the 
site of surgical operation was disinfected with Anerdian, the skin 
was cut open in transverse direction at about 5 mm downward from 
xiphoid process to expose the liver, the prepared tumor tissue mass 
was sewed with surgical sutures on the side of left lobe of mouse 
liver closed to the middle lobe of liver, and the skin was sutured 
layer by layer, sterilized with Anerdian, the mice were put back to 
the cage to breed. Test with small animal in-vivo imaging system at 
7 d after surgical operation was performed. 
2.6. Therapeutic effect of compound HS-4 in orthotopic 
xenotransplanted tumor of liver cancer
  After orthotopic xenotransplanted tumor model of liver cancer 
was established, random assignment was performed in animals 
according to the data about tumor tested by small animal in-vivo 
imaging system, the mice were divided into HS-4 group and solvent 
control group in the experiment, wherein, HS-4 was classified into 
3 dose groups based on the dosage provided as 4, 2 and 10 mg/kg, 
respectively. There were 6 animals in each group, and sintragastric 
administration was provided. Time of drug administration: 14 d.
2.7. Data analysis
  SPSS statistical analytical software was used to perform variance 
analysis in experimental data, and the difference between HS-4 
group and solvent control group was compared.
3. Results
3.1. Screening of in vitro antitumor activity of the compound 
HS-4
  MTT method was used to screen in vitro antitumor activity of the 
compound HS-4. Cell lines included human liver cancer cell Bel-
7402, human liver cancer cell SMMC-7721, human gastric cancer 
cell MGC-803, human gastric cancer cell SGC-7901, human 
breast cancer cell MCF-7, human cervical cancer cell Hela, human 
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esophageal cancer cell TE-1, human lung cancer cell A549, human 
lung cancer cell NCI-H446, human colon cancer cell HT-29, human 
kidney cancer cell ACHN and human leukemia cell HL-60. The 
results of experiment were shown in Table 1. It was indicated by the 
results that, compound HS-4 had relatively high tumor inhibitory 
rates against all above tumor cells. The IC50 values against liver 
cancer cell SMMC-7721and Bel-7402 were 0.14 and 0.13 nmol/L 
respectively, and the IC50 values against gastric cancer cell MGC-803 
and SGC-7901 were 0.19 and 0.21 nmol/L respectively. 
Table 1
Antitumor activity of HS-4 in vitro.
Cell Tumor type IC50 (nmol/L)
Bel-7402 Liver 0.13
SMMC-7721 Liver 0.14
MGC-803 Stomach 0.19
SGC-7901 Stomach 0.21
MCF-7 Breast 0.31
Hela Uterus 0.44
TE-1 Esophgus 0.67
A549 Lung 0.54
NCI-H446 Lung 0.68
HT-29 Colon 0.46
ACHN Kidney 1.24
HL-60 Leukemia 3.41
3.2. Investigation on therapeutic effect of compound HS-4 in 
subcutaneously xenotransplanted tumor
  Investigations have been performed on therapeutic effect of 
compound HS-4 in subcutaneously xenotransplanted tumor against 
11strains of tumor cells except HL-60. It was demonstrated by the 
results that, the best therapeutic effect of HS-4 was achieved in 
treatment of liver cancer, and the result was shown in Table 2. At 
3W after intragastric drug administration was performed, tumor 
inhibitory rates against 11 tumors implanted were all over 65% in 
dose group of 2 mg/kg, while tumor inhibitory rates in dose group of 
10 mg/kg were all over 80%, and the tumor inhibitory rates against 
the other 7 tumors except breast cancer, lung cancer and kidney 
cancer in dose group of 0.4 mg/kg were all over 40%. 
Table 2 
Antitumor activity of HS-4 in vitro.
Cell Tumor type
Initial tumor
volume(mm3)
TCI%
0.4 mg/kg 2 mg/kg 10 mg/kg
Bel-7402 Liver 393 53.7* 82.6* >100*
SMMC-7721 Liver 362 50.9* 80.1* >100*
MGC-803 Stomach 426 48.8* 76.4* 97.4*
SGC-7901 Stomach 384 41.4* 71.6* 98.6*
MCF-7 Breast 433 32.7 68.8* 86.4*
Hela Uterus 410 40.3* 70.9* 82.7*
TE-1 Esophgus 326 46.3* 66.2* 82.4*
A549 Lung 462 26.8 70.6* 83.1*
NCI-H446 Lung 428 28.4 68.4* 85.7*
HT-29 Colon 468 50.8* 80.2* 91.4*
ACHN Kidney 360 33.4 73.4* 94.3*
NOTE: The percentage of tumor-growth inhibition (TGI%) compared with 
the vehicle-treated group was calculated on the day after the last treatment 
(day 14), *P<0.05.
3.3. Investigation on therapeutic effect of HS-4 in orthotopic 
xenotransplanted tumor of liver cancer Bel-7402
  According to the investigation on therapeutic effect of HS-4 in 
subcutaneously xenotransplanted tumor in Table 2, the liver cancer 
cell Bel-7402 in which the best therapeutic effect was achieved was 
selected to perform orthotopic xenotransplantation, so as to identify 
the therapeutic effect of HS-4 in liver cancer. During the experiment, 
IVIS small animal in-vivo imaging system was used to effectively 
detect the growth of tumor. It could be seen from Figure 1B, the 
amount of tumor cells in 3 dose groups of HS-4 was significantly 
lower than that in solvent control group, and significant dose-effect 
relationship was presented, indicating that the growth of tumor cells 
were significantly controlled. Growth of tumor tissue in solvent 
control group and HS-4 group (dosage was 10 mg/kg) was shown in 
Figure 2. It was shown by the results that, tumor tissue was relatively 
small in HS-4 group, while the tumor tissue was clearly seen in 
solvent control group. Comparison of tumor cell quantity before and 
after drug administration between animals in HS-4 group (dosage 
was 10 mg/kg) and solvent control group was shown in Figure 3. At 
3W after drug administration, the amount of tumor cells in solvent 
control group was significantly increased, while the amount of tumor 
cells in HS-4 group was significantly decreased, wherein, live tumor 
cells could not be detected in animal No.3, while the amount of live 
tumor cells were hardly detected in animal No.5.
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Figure 1. Antitumor activity of HS-4 in vivo.
(A) chemical structure ofHS-4.(B) HS-4 inhibits the growth of established 
Bel-7402 tumor xenografts in athymic mice.
 
Figure 2. Effect of HS - 4 for liver cancer Bel - 7402 nude mouse orthotopic 
transplantation tumor therapy. 
(A) Vehicle, (B) Glup of HS-4,10 mg/kg for 21days.
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HS-4 (10 mg/kg)                                              Vehicle
Day 7 –Day dosing began
Day 21 –Last measurement
 
Figure 3. Photon emission from individual mice was visualized before 
administration of the first dose of HS-4 or vehicle (day 7) and afterthe last 
measurement (day 21). 
Red color indicates more fluorescence indicative of a greater number of live 
tumor cells. Daily oral administration of HS-4 at 10 mg/kg/day was initiated 
when the tumors reached an average size.
4. Discussion
  HS-4 is a compound isolated from Mangrove Kandelia candel. It 
was demonstrated by relevant studies that, the primary structure of 
HS-4-geniposidic acid could be used in protecting against cancer 
caused by radiation[4]. It was indicated by the study performed 
by Tang that, compound 6,6’-bis (2,3-dimethoxybenzoyl)-a, a-D-
trehalose (DMBT) had relatively high anti tumor invasion and 
metastasis activity, of which the anti invasion activity against 
colon cancer cell 26-L5 was even higher than that of the natural 
product-Brartemicin, where the IC50 was 0.15 毺M (0.10毺g/mL)
[5]. This proved the fact effectively from another perspective that, 
HS-4 [10-(4’-hydroxy-3’,5’ –dimethoxybenzoyl)-geniposidic 
acid] had relatively high antitumor activity. It was proved by 
extensive screening of in vivo antitumor activity against in vitro 
or subscutaneously xenotransplanted tumor and orthotopic 
xenotransplanted tumor and analysis in small RNA of tumor cells 
that, HS-4 had relatively excellent therapeutic effect in tumor with 
significant difference compared to that in solvent control group.
  During the process of therapeutic experiment in subscutaneously 
xenotransplanted tumor, excellent antitumor activity was presented in 
HS-4 which achieved powerful therapeutic effect in xenotransplanted 
solid tumors of human tumor cells in nude mice, such as Bel-7402, 
SMMC-7721, MGC-803, SGC-7901, MCF-7, Hela, TE-1, A549, 
NCI-H446, HT-29, ACHN, etc, having very highly positive prospect 
of development. 
  Primary liver cancer is one of the common malignant tumors in 
the world. As for the method of orthotopic xenotransplantation of 
liver cancer in nude mice[6-8], traditionally, a blunt object is applied 
to make a hole in the liver of mouse,  hemostasis is performed by 
compression after tumor tissue mass is put inside, or the tumor 
tissue mass is just sealed inside with biocolloid. But the method 
will result in relatively serious damage to the liver of mouse as well 
as massive bleeding likely. Therefore, a new method for orthotopic 
xenotransplantation have been established: that the tumor tissue 
mass was sewed on the side of left lobe of mouse liver closed to the 
middle lobe of liver, which can effectively help avoid adhesion of 
tumor tissue with other tissues except liver. In addition, be careful 
to wash the likely drop-off cells at the surface of tumor tissue mass 
with culture solution so as to avoid extensive implantation of tumor 
in abdominal cavity. 
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